Skip to main content
Clinical Trials/NCT00759369
NCT00759369CompletedNot Applicable

Water as Therapy in Autosomal Dominant Polycystic Kidney Disease

University of Kansas1 site in 1 country11 target enrollmentStarted: September 1, 2008Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
11
Locations
1
Primary Endpoint
Percentage of mean urine osmolality decreased from baseline

Study Overview

Brief Summary

Autosomal dominant polycystic kidney disease (ADPKD) is the most common single gene disorder that is potentially fatal. ADPKD is caused by mutations in either of two genes (PKD1, PKD2). Cysts begin to develop primarily in renal collecting tubules in utero and continue to form and expand throughout the patient's life. One of the goals of the study is to formulate a water prescription for use in clinical trials to determine the effect of sustained water diuresis on the progression of ADPKD.

Detailed Description

The proposed study will devise a quantitative model to estimate the amount of water an individual would need to ingest in order to lower the 24 h mean urine osmolality to a level below plasma (~285 mOsm/Kg). This osmolality goal is chosen because the 24h median urine osmolality of humans is ordinarily ~753 mOsm/Kg, much greater than 285 mosm/Kg (6, 7). In other words, normal humans are usually anti-diuretic during waking hours and while asleep. Median 24h urine volume is ~1225 ml (range 1051 - 2270). In temperate climates the insensible losses of water in sweat, respiration and stool are nearly balanced by the water ingested in solid and semi-solid foods and derived from metabolism. Thus, daily urine volume measured upon arising in the morning is a reasonably good indicator of the volume of fluids drunk over the preceding 24 h.

Study Design

Study Type
Interventional
Allocation
Non Randomized
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to 50 Years (Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •ADPKD verified by ultrasound, CT or MRI, family history or physical exam
  • •Normal creatinine clearance, calculated by Cockroft-Gault formulat
  • •Good general health
  • •Controlled blood pressure, < 140/90
  • •Absence of urinary tract symptoms such as dysuria, hesitancy, diminished flow

Exclusion Criteria

  • •Uncontrolled hypertension
  • •Urinary tract symptoms, dysuria, hesitancy, diminished flow, gross hematuria
  • •Diabetes mellitus, cancer, hematologic disorder
  • •Unable to follow directions
  • •Solitary kidney
  • •History of CHF, liver dysfunction or hyponatremia
  • •Currently taking diuretics
  • •Nephrotic range proteinuria (3.5 g/day)

Arms & Interventions

1

Experimental

Water prescription

Intervention: Water prescription (Other)

Outcomes

Primary Outcomes

Percentage of mean urine osmolality decreased from baseline

Time Frame: Day 3, 4, 5

Secondary Outcomes

  • Number of individuals who have an average daily solute excretion within 16.5% of baseline(End of study)
  • Number of individuals whose average total urine volume is within 18% of baseline.(End of study)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials